Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors

Damiani, D. Doḿınguez; Tiribelli, Mario; Raspadori, Donatella; Sirianni, Santina; Meneghel, Alessia; Cavalllin, Margherita; Michelutti, Angela; Toffoletti, Eleonora; Geromin, Antonella; Simeone, Ester; Bocchia, Monica; Fanin, Renato

doi:10.18632/oncotarget.4901

Cited by 36 publications

(35 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CD200, the ligand for inhibitory CD200R, was found to be a prognostic factor for multiple myeloma [216] and was increased in more than 50% of the patients with acute myeloid leukemia. This increased expression, moreover, correlates with a lower probability for complete remission [160,217]. That CD200R signaling is involved in tumor progression was demonstrated in vivo, because CD200 −/− mice had a later onset and less chemically-induced skin papillomas compared to wild type mice.…”

Section: Cancermentioning

confidence: 95%

See 1 more Smart Citation

Immunoreceptors on neutrophils

Rees

Szilagyi

Kuijpers

et al. 2016

Seminars in Immunology

View full text Add to dashboard Cite

Neutrophils play a critical role in the host defense against infection, and they are able to perform a variety of effector mechanisms for this purpose. However, there are also a number of pathological conditions, including autoimmunity and cancer, in which the activities of neutrophils can be harmful to the host. Thus the activities of neutrophils need to be tightly controlled. As in the case of other immune cells, many of the neutrophil effector functions are regulated by a series of immunoreceptors on the plasma membrane. Here, we review what is currently known about the functions of the various individual immunoreceptors and their signaling in neutrophils. While these immunoreceptors allow for the recognition of a diverse range of extracellular ligands, such as cell surface structures (like proteins, glycans and lipids) and extracellular matrix components, they commonly signal via conserved ITAM or ITIM motifs and their associated downstream pathways that depend on the phosphorylation of tyrosine residues in proteins and/or inositol lipids. This allows for a balanced homeostatic regulation of neutrophil effector functions. Given the number of available immunoreceptors and their fundamental importance for neutrophil behavior, it is perhaps not surprising that pathogens have evolved means to evade immune responses through some of these pathways. Inversely, some of these receptors evolved to specifically recognize these pathogens. Finally, some interactions mediated by immunoreceptors in neutrophils have been identified as promising targets for therapeutic intervention.

show abstract

Section: Cancermentioning

confidence: 95%

“…For instance, CD200R was found to attenuate inflammation in neurodegenerative and cardiovascular disorders, and also in allergy [159]. Pathogens and cancer cells may have evolved means that result in immune evasion: CD200 is up-regulated in leukemias and large DNA viruses including herpes-and poxviruses, seem to bind CD200 [159][160][161].…”

Section: Cd200rmentioning

confidence: 99%

Immunoreceptors on neutrophils

Rees

Szilagyi

Kuijpers

et al. 2016

Seminars in Immunology

View full text Add to dashboard Cite

show abstract

“…Blast cells immunophenotype was obtained by multiparametric flow cytometry (Facs Canto, BD, Brussel, Belgium and Diva software), considering as “positive” the cases expressing the tested antigen in more than 20% of cells. CD200 and Bcl2 intensity were calculated by the mean fluorescence index (MFI, ie, the ratio between the mean florescence intensity of the test and that of its isotypic control), with cutoff values discriminating overexpressing (positive) cases of 11 for CD200 and 17 for Bcl2, respectively . ABCG2 protein intensity of expression was calculated by Kolmogorov‐Smirnov: a D‐value of 0.3 defined overexpressing (ABCG2+) cases…”

Section: Methodsmentioning

confidence: 99%

ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML

Tiribelli

Geromin

Cavallin

et al. 2017

European J of Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…CD200 can be expressed on the surface of malignant cells and result in tumor immune escape (54, 56). In adult AML, expression of CD200 correlated with lower natural killer (NK) cell numbers, increased frequency of Tregs, and a worse prognosis (16, 57). …”

Section: Introductionmentioning

confidence: 99%

Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy

Ring

Markert

Gillespie

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Pediatric brain and extracranial solid tumors are a diverse group of malignancies that represent almost half of pediatric cancers. Standard therapy includes various combinations of surgery, cytotoxic chemotherapy and radiation, which can be very harmful to a developing child, and survivors carry a substantial burden of long term morbidities. While these therapies have improved survival rates for children with solid tumors, outcomes still remain extremely poor for subsets of patients. Recently, immunosuppressive checkpoint molecules that negatively regulate immune cell function have been described. When found on malignant cells or in the tumor microenvironment, they contribute to immune evasion and tumor escape. Agents designed to inhibit these proteins have demonstrated significant efficacy in human adult solid tumor studies. However, there is limited research focusing on immune checkpoint molecules and inhibitors in pediatric solid tumors. In this review, we examine the current knowledge on immune checkpoint proteins with an emphasis on Cytotoxic T Lymphocyte Antigen-4 (CTLA-4); Programmed cell Death protein-1 (PD-1) and Programmed Death Ligand 1 (PD-L1); OX-2 membrane glycoprotein (CD200); and Indoleamine 2,3-dioxygenase (IDO). We review T cell signaling, the mechanisms of action of these checkpoint molecules, pediatric preclinical studies on checkpoint proteins and checkpoint blockade, pediatric checkpoint inhibitor clinical trials conducted to date, and future immunotherapy opportunities for childhood cancers.

show abstract

Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors

Cited by 36 publications

References 53 publications

Immunoreceptors on neutrophils

Immunoreceptors on neutrophils

ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML

Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy

Contact Info

Product

Resources

About